Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing ...

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...

Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound.  For many consumers, their insurance denies them ...

Key Takeaways Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of ...

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...

Denzel Washington has fans doing a double take after noticing the A-lister’s recent transformation. Washington, 70, has been ushering in a more healthy ...

Top medics have issued urgent warnings after fat jabs including celebrity favourite Ozempic are inked with 82 deaths, as drug ...

Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...

Goldberg has been open about her own weight loss on The View. During a March 2024 episode of the show, she disclosed that she ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to continue ...